Gene therapy for human colorectal cancer cell lines with recombinant adenovirus 5 based on loss of the insulin-like growth factor 2 imprinting

Sun,Huiling; Pan,Yuqin; He,Bangshun; Deng,Qiwen; Li,Rui; Xu,Yeqiong; Chen,Jie; Gao,Tianyi; Ying,Houqun; Wang,Feng; Liu,Xian; Wang,Shukui

doi:10.3892/ijo.2015.2852

Gene therapy for human colorectal cancer cell lines with recombinant adenovirus 5 based on loss of the insulin-like growth factor 2 imprinting

Authors:
- Huiling Sun
- Yuqin Pan
- Bangshun He
- Qiwen Deng
- Rui Li
- Yeqiong Xu
- Jie Chen
- Tianyi Gao
- Houqun Ying
- Feng Wang
- Xian Liu
- Shukui Wang
View Affiliations

Affiliations: Department of Life Sciences, Nanjing Normal University, Nanjing, Jiangsu 210006, P.R. China, Central Laboratory, Nanjing First Hospital, Nanjing Medical University, Nanjing, Jiangsu 210006, P.R. China, Medical College, Southeast University, Nanjing, Jiangsu 210009, P.R. China
Published online on: January 26, 2015 https://doi.org/10.3892/ijo.2015.2852
Pages: 1759-1767

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The recombinant oncolytic adenovirus is a novel anticancer agent to replicate selectively in colon cancer cell lines. Loss of imprinting (LOI) of insulin-like growth factor 2 (IGF2) gene is an epigenetic abnormality phenomenon. We utilized the IGF2 LOI in gene therapy for the malignant tumor cell lines. We investigated the tumoricidal effects of IGF2 LOI on four cell lines by oncolytic adenovirus, and constructed novel adenovirus vectors Ad312-E1A and Ad312-EGFP. The expression of E1A was monitored by real‑time PCR and western blot analysis. The viability and apoptosis of colorectal cells infected with Ad312-E1A were tested by CCK-8 and flow cytometry. In addition, we established a colorectal cancer model in nude mice. The results showed that HCT-8 and HT-29 with IGF2 LOI were infected with Ad312-EGFP and then produced the EGFP. Nevertheless, SW480 and GES-1, which were IGF2 MOI, did not produce the EGFP. The Ad312-E1A obviously reduced the cell viability and induced apoptosis in HCT-8 and HT-29 in vitro, and successfully suppressed tumor growth in HT-29 xenografts in nude mice. In summary, the conditionally replicative adenovirus with loss of IGF2 imprinting system has a positive effect on gene therapy.

View Figures

View References

1	Siegel R, Naishadham D and Jemal A: Cancer statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
2	Houlston RS, Collins A, Slack J and Morton NE: Dominant genes for colorectal cancer are not rare. Ann Hum Genet. 56:99–103. 1992. View Article : Google Scholar : PubMed/NCBI
3	Fu VX, Dobosy JR, Desotelle JA, et al: Aging and cancer-related loss of insulin-like growth factor 2 imprinting in the mouse and human prostate. Cancer Res. 68:6797–6802. 2008. View Article : Google Scholar : PubMed/NCBI
4	Engstrom W, Shokrai A, Otte K, et al: Transcriptional regulation and biological significance of the insulin like growth factor II gene. Cell Prolif. 31:173–189. 1998. View Article : Google Scholar
5	Engel N, Thorvaldsen JL and Bartolomei MS: CTCF binding sites promote transcription initiation and prevent DNA methylation on the maternal allele at the imprinted H19/Igf2 locus. Hum Mol Genet. 15:2945–2954. 2006. View Article : Google Scholar : PubMed/NCBI
6	Pan Y, He B, Li T, et al: Targeted tumor gene therapy based on loss of IGF2 imprinting. Cancer Biol Ther. 10:290–298. 2010. View Article : Google Scholar : PubMed/NCBI
7	Nevins JR, Ginsberg HS, Blanchard JM, Wilson MC and Darnell JE Jr: Regulation of the primary expression of the early adenovirus transcription units. J Virol. 32:727–733. 1979.PubMed/NCBI
8	Breyer B, Jiang W, Cheng H, et al: Adenoviral vector-mediated gene transfer for human gene therapy. Curr Gene Ther. 1:149–162. 2001. View Article : Google Scholar
9	Yamada M, Lewis JA and Grodzicker T: Overproduction of the protein product of a nonselected foreign gene carried by an adenovirus vector. Proc Natl Acad Sci USA. 82:3567–3571. 1985. View Article : Google Scholar : PubMed/NCBI
10	Ballay A, Levrero M, Buendia MA, Tiollais P and Perricaudet M: In vitro and in vivo synthesis of the hepatitis B virus surface antigen and of the receptor for polymerized human serum albumin from recombinant human adenoviruses. EMBO J. 4:3861–3865. 1985.PubMed/NCBI
11	Pollak MN, Schernhammer ES and Hankinson SE: Insulin-like growth factors and neoplasia. Nat Rev Cancer. 4:505–518. 2004. View Article : Google Scholar : PubMed/NCBI
12	Ito Y, Koessler T, Ibrahim AE, et al: Somatically acquired hypomethylation of IGF2 in breast and colorectal cancer. Hum Mol Genet. 17:2633–2643. 2008. View Article : Google Scholar : PubMed/NCBI
13	Kaneda A and Feinberg AP: Loss of imprinting of IGF2: a common epigenetic modifier of intestinal tumor risk. Cancer Res. 65:11236–11240. 2005. View Article : Google Scholar : PubMed/NCBI
14	Suzuki H, Ueda R and Takahashi T: Altered imprinting in lung cancer. Nat Genet. 6:332–333. 1994. View Article : Google Scholar : PubMed/NCBI
15	Oda H, Kume H, Shimizu Y, Inoue T and Ishikawa T: Loss of imprinting of igf2 in renal-cell carcinomas. Int J Cancer. 75:343–346. 1998. View Article : Google Scholar : PubMed/NCBI
16	Mori M, Inoue H, Shiraishi T, et al: Relaxation of insulin-like growth factor 2 gene imprinting in esophageal cancer. Int J Cancer. 68:441–446. 1996. View Article : Google Scholar : PubMed/NCBI
17	Hibi K, Nakamura H, Hirai A, et al: Loss of H19 imprinting in esophageal cancer. Cancer Res. 56:480–482. 1996.PubMed/NCBI
18	Yun K, Fukumoto M and Jinno Y: Monoallelic expression of the insulin-like growth factor-2 gene in ovarian cancer. Am J Pathol. 148:1081–1087. 1996.PubMed/NCBI
19	Li T, Hu JF, Qiu X, et al: CTCF regulates allelic expression of Igf2 by orchestrating a promoter-polycomb repressive complex 2 intrachromosomal loop. Mol Cell Biol. 28:6473–6482. 2008. View Article : Google Scholar : PubMed/NCBI
20	Rakha EA, Pinder SE, Paish CE and Ellis IO: Expression of the transcription factor CTCF in invasive breast cancer: a candidate gene located at 16q22.1. Br J Cancer. 91:1591–1596. 2004. View Article : Google Scholar : PubMed/NCBI
21	Yang Y, Hu JF, Ulaner GA, et al: Epigenetic regulation of Igf2/H19 imprinting at CTCF insulator binding sites. J Cell Biochem. 90:1038–1055. 2003. View Article : Google Scholar : PubMed/NCBI
22	Paradowska A, Fenic I, Konrad L, et al: Aberrant epigenetic modifications in the CTCF binding domain of the IGF2/H19 gene in prostate cancer compared with benign prostate hyperplasia. Int J Oncol. 35:87–96. 2009. View Article : Google Scholar : PubMed/NCBI
23	Szabo PE, Tang SH, Silva FJ, Tsark WM and Mann JR: Role of CTCF binding sites in the Igf2/H19 imprinting control region. Mol Cell Biol. 24:4791–4800. 2004. View Article : Google Scholar : PubMed/NCBI
24	Liu M, Roth A, Yu M, et al: The IGF2 intronic miR-483 selectively enhances transcription from IGF2 fetal promoters and enhances tumorigenesis. Genes Dev. 27:2543–2548. 2013. View Article : Google Scholar : PubMed/NCBI
25	Rainier S, Johnson LA, Dobry CJ, Ping AJ, Grundy PE and Feinberg AP: Relaxation of imprinted genes in human cancer. Nature. 362:747–749. 1993. View Article : Google Scholar : PubMed/NCBI
26	Ogawa O, Eccles MR, Szeto J, et al: Relaxation of insulin-like growth factor II gene imprinting implicated in Wilms’ tumour. Nature. 362:749–751. 1993. View Article : Google Scholar : PubMed/NCBI
27	Ekstrom TJ, Cui H, Li X and Ohlsson R: Promoter-specific IGF2 imprinting status and its plasticity during human liver development. Development. 121:309–316. 1995.PubMed/NCBI
28	Ohlsson R, Nystrom A, Pfeifer-Ohlsson S, et al: IGF2 is parentally imprinted during human embryogenesis and in the Beckwith-Wiedemann syndrome. Nat Genet. 4:94–97. 1993. View Article : Google Scholar : PubMed/NCBI
29	Nakagawa H, Chadwick RB, Peltomaki P, Plass C, Nakamura Y and de La Chapelle A: Loss of imprinting of the insulin-like growth factor II gene occurs by biallelic methylation in a core region of H19-associated CTCF-binding sites in colorectal cancer. Proc Natl Acad Sci USA. 98:591–596. 2001. View Article : Google Scholar :
30	Cui H: Loss of imprinting of IGF2 as an epigenetic marker for the risk of human cancer. Dis Markers. 23:105–112. 2007. View Article : Google Scholar : PubMed/NCBI
31	Baba Y, Nosho K, Shima K, et al: Hypomethylation of the IGF2 DMR in colorectal tumors, detected by bisulfite pyrosequencing, is associated with poor prognosis. Gastroenterology. 139:1855–1864. 2010. View Article : Google Scholar : PubMed/NCBI
32	Tricoli JV, Rall LB, Karakousis CP, et al: Enhanced levels of insulin-like growth factor messenger RNA in human colon carcinomas and liposarcomas. Cancer Res. 46:6169–6173. 1986.PubMed/NCBI
33	Lambert S, Vivario J, Boniver J and Gol-Winkler R: Abnormal expression and structural modification of the insulin-like growth-factor-II gene in human colorectal tumors. Int J Cancer. 46:405–410. 1990. View Article : Google Scholar : PubMed/NCBI
34	Cui H, Cruz-Correa M, Giardiello FM, et al: Loss of IGF2 imprinting: a potential marker of colorectal cancer risk. Science. 299:1753–1755. 2003. View Article : Google Scholar : PubMed/NCBI
35	Garber K: China approves world’s first oncolytic virus therapy for cancer treatment. J Natl Cancer Inst. 98:298–300. 2006. View Article : Google Scholar : PubMed/NCBI
36	Holm PS, Lage H, Bergmann S, et al: Multidrug-resistant cancer cells facilitate E1-independent adenoviral replication: impact for cancer gene therapy. Cancer Res. 64:322–328. 2004. View Article : Google Scholar : PubMed/NCBI